Lukair is used as part of symptomatic management for conditions characterized by periods of heightened symptoms related to chronic asthma, seasonal or perennial allergies, and symptoms triggered by exertion.

This medication is used in areas where additional symptomatic support is needed, helping to manage symptoms that create noticeable physiological strain. The core indications include supportive management for conditions involving episodic or fluctuating manifestations like chronic asthma, the easing of allergic rhinitis symptoms (such as sneezing and congestion), and addressing the symptoms associated with acute or episodic changes triggered by exercise.

Patients often seek this support during phases when symptoms become more noticeable.

“This use contributes to improved comfort during periods of heightened symptoms.”

Quick Fact: Relief for Wheezing and Nasal Symptoms

Lukair is commonly used to help with symptom clusters that may become intense or disruptive, such as the coughing and wheezing seen in asthma, and the combined itchy eyes and nasal congestion often associated with allergies. This application assists with maintaining functional stability during symptomatic periods.

Regulatory References

1. NIH MedlinePlus overview of Montelukast

Lukair (montelukast) is subject to specific regulatory eligibility rules that define the patient populations for whom its use is formally permitted, restricted, or prohibited.

Contraindications and Restrictions

Classification	Rule
Absolute Prohibition	Patients with known hypersensitivity or allergy to montelukast or any of its components must not use Lukair.
Acute Event Exclusion	The medication is not indicated for the reversal of acute asthma attacks or status asthmaticus; patients must rely on separate rescue medication.

Age and Special Population Eligibility

Eligibility is defined by minimum age and the specific condition being treated. While the medication is approved for adults and adolescents 15 years and older, use in pediatric patients is age-dependent:

• Children under 12 months are not eligible for asthma treatment as safety and efficacy have not been established.
• Children under 6 years are not eligible for the prevention of exercise-induced bronchoconstriction.

For pregnant and breastfeeding women, official labeling states that use is advised only if clearly needed or considered clearly essential. Additionally, the chewable tablets contain phenylalanine, requiring caution for patients with phenylketonuria (PKU).

Lukair (montelukast) interacts with certain other medicines, primarily those that influence the liver enzymes responsible for its metabolism.

Documented Pharmacokinetic Interactions

Lukair is metabolized by the liver’s cytochrome P450 enzymes, specifically CYP3A4, 2C8, and 2C9. Drugs that strongly induce these enzymes can reduce the amount of Lukair in the bloodstream, potentially lessening its clinical effect.

Interacting Product Category	Examples Listed in Official Labeling	Potential Effect on Lukair
Potent Enzyme Inducers	Rifampin, Phenytoin, Carbamazepine	May decrease Lukair plasma concentration (up to 40% with Rifampin)
Herbal Supplements	St. John’s Wort	Potential for decreased Lukair effect

No dosage adjustment for Lukair is typically recommended when coadministered with Rifampin, despite the noted decrease in concentration.

Other Clinically Relevant Interactions

• Oral Anticoagulants (e.g., Warfarin): While clinical studies did not demonstrate clinically significant changes to prothrombin time with coadministration, patients taking a stable dose may require continued monitoring.
• Aspirin and NSAIDs: Patients with known aspirin sensitivity must continue to avoid aspirin and other non-steroidal anti-inflammatory agents (NSAIDs) while taking Lukair, as these medications may trigger bronchospasm in sensitive individuals.

Lukair itself does not inhibit the metabolism of many common medications, and no clinically important effects were observed when coadministered with agents such as theophylline, prednisone, or oral contraceptives.

Selective Antagonism of the CysLT1 Receptor

Lukair functions as a highly selective antagonist by competitively binding to the Cysteinyl Leukotriene Type-1 Receptor (CysLT1), the principal target for the pro-inflammatory leukotrienes (LTD4, LTC4, LTE4). This molecular blockade prevents the natural ligands from initiating cellular signaling, which modulates the leukotriene cascade in the airways.

Dual Physiological Consequences of the Mechanism

This competitive blockade results in two distinct physiological effects. Firstly, it inhibits the signal for smooth muscle contraction in the air passages. Secondly, it mitigates signaling that promotes increased vascular permeability and inflammatory cell recruitment. This dual mechanistic consequence influences the long-term regulation of airway smooth muscle tone and inflammatory processes.

Specificity and Temporal Constraint of the Mechanism

Lukair's action is entirely specific to the CysLT1 pathway. Consequently, the molecule does not interfere with inflammatory processes mediated by other systems, such as histamine or prostaglandins. While the anti-constrictive effect begins rapidly due to receptor saturation, the complete manifestation of the anti-inflammatory effect requires sustained pathway modulation over time. This action profile is mechanistically constrained and does not rapidly reverse existing bronchospasm.

Official Administration of Lukair (Montelukast)

Lukair is an oral medication that must be taken continuously for long-term management, consistent with a maintenance regimen. It is available in three official forms—film-coated tablets, chewable tablets, and oral granules—each with specific handling requirements.

---

Standard Dosing and Timing

Age Group	Standard Daily Dose	Dosing Timing	Dosing Form
Adults (≥ 15 years)	10 mg	Once daily (usually evening)	Film-coated tablet
Pediatric (6–14 years)	5 mg	Once daily (usually evening)	Chewable tablet
Pediatric (2–5 years)	4 mg	Once daily (usually evening)	Chewable tablet or Granules

For chronic respiratory conditions, the dose should be taken once daily in the evening. For allergic rhinitis alone, the administration time may be individualized (morning or evening). The medication may be taken with or without food.

---

Preparation and Special Conditions

Oral Granules

The full dose of oral granules must be administered within 15 minutes of opening the packet. It may be swallowed directly or mixed with a spoonful of cold or room temperature soft foods, such as applesauce, carrots, rice, or ice cream, or dissolved in 5 mL of baby formula or breast milk. Granules must not be stored for future use after mixing.

Exercise-Induced Prevention

For prevention of exercise-induced bronchoconstriction (EIB), a single dose must be taken at least two hours before exercise. An additional dose must not be taken within 24 hours of a previous dose. Patients already on a daily maintenance dose should not take an extra EIB dose.

Missed Dose

If a dose is missed, the standard procedure is to skip the missed dose and take the next dose at the regular scheduled time. Do not take two doses to compensate for the missed one.

Research Evidence / Overview of Studies for Lukair

Lukair (montelukast) has been subject to clinical evaluation through various types of research, including randomized controlled trials (RCTs), comparative studies, systematic reviews, and long-term observational studies. This overview describes the structure of the evidence used by regulatory bodies, focusing on the conditions studied and the limitations of the existing data, without providing medical advice or recommendations.

---

Evidence for Use in Chronic Asthma

Lukair was studied for the long-term management of asthma, a condition characterized by fluctuating or episodic manifestations. The studies explored how symptoms change over time and measured outcomes such as changes in lung function (like FEV1), reduction in the frequency of acute episodes or exacerbations, and recorded use of rescue inhalers. Findings from these controlled studies reported measured changes in lung function and indicated patterns related to the monitored use of rescue medication compared to placebo. When studied alongside inhaled corticosteroids (ICS), research described observations where patients maintained certain clinical parameters. Long-term outcomes, particularly those related to the sustained maintenance of clinical metrics or effects beyond two years, are not fully characterized. Data for certain patient subgroups, such as those with severe, uncontrolled asthma, remain limited.

---

Evidence for Use in Exercise-Induced Bronchoconstriction (EIB)

Research examined Lukair for use in research exploring symptoms related to physical activity. This was primarily conducted through short-term, placebo-controlled trials often using a standardized exercise challenge. Data show patterns related to the measured decline in FEV1 measurements following the challenge compared to placebo. Research provides insight into short-term changes, documenting that the observed change was recorded across the entire 24-hour interval following daily dosing in certain observed populations. Data for children under six years old remains limited, and comparative evidence against other acute prevention strategies is often lacking in the long-term context.

---

What is Still Uncertain About the Research

The research provides context but not individual predictions, and evidence highlights what is known—and what is still uncertain. Data for certain groups remain limited, and for some indications, follow-up durations were limited to short- to medium-term periods, meaning long-term effects are not fully characterized. Furthermore, official scientific literature describes patterns of variability in individual response observed in some studies, and research describing these subgroup patterns remains limited. Findings describe group patterns, not personal outcomes.

Common questions about Lukair (FAQ)

---

Q: What are the common side effects I should look out for when starting Lukair?

Official documentation reports upper respiratory infection as the most common side effect observed in clinical trials, classified as very common.

Other side effects commonly reported in trials include abdominal pain, diarrhea, nausea, headache, fever, and rash.

---

Q: What should I mix the oral granules with?

Official labeling states that the oral granules may be swallowed directly or mixed with a spoonful of cold or room temperature soft foods. Examples listed include applesauce, carrots, rice, or ice cream.

Alternatively, the granules can be dissolved in 5 mL of baby formula or breast milk. The entire mixture must be administered within 15 minutes of opening the packet.

---

Q: What is the recommended storage temperature for the tablets?

Lukair tablets are required to be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F).

To ensure product stability as directed by the label, the medication must also be kept protected from both moisture and light.

---

Q: If I’m taking Lukair for allergies, what is the best time of day to take it?

Official information for allergic rhinitis indicates that the time of administration may be individualized.

Studies demonstrated efficacy when the dose was taken in the morning or the evening, indicating flexibility in scheduling.

---

Q: How long does it take for Lukair to start working for asthma symptoms?

Studies indicate the medicine is rapidly absorbed after the first dose. While the anti-constrictive effect begins quickly, the full anti-inflammatory effect—key for long-term asthma management—requires sustained daily use over time to achieve its maximum benefit.

---

Q: Can I take Lukair at the same time as my daily inhaled corticosteroid?

Official documentation indicates that Lukair and inhaled corticosteroids may be used concomitantly (together) as part of a maintenance regimen.

However, regulatory documents caution that Lukair is not intended to be substituted abruptly for inhaled or oral corticosteroids.

---

Lukair (montelukast sodium) must be stored and disposed of based strictly on official regulatory labeling to ensure product stability and safety.

Storage Condition	Requirement
Temperature	Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F), with permitted excursions to 30 C [Source 4.2].
Protection	Keep the medicine in the original container and protect from moisture and light [Source 4.2].
Child Safety	Store the product out of the sight and reach of children [Source 4.4].
Oral Granules Stability	Once the packet is opened, the full dose must be administered within 15 minutes [Source 2.1]. Do not store mixed oral granules for future use [Source 2.1].

Unused or expired product should be disposed of using a community-based drug take-back program when available [Source 3.1]. If a take-back program is unavailable, follow the household disposal steps by mixing the medicine with an undesirable substance before discarding it in the trash [Source 3.1]. Before disposal, scratch out all personal information on the prescription label [Source 3.1].